ArticleBioData mining2025
Towards precision oncology: a multi-level cancer classification system integrating liquid biopsy and machine learning.
Article in BioData mining, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Machine learning and artificial intelligence in liquid biopsy-based early detection of pancreatic cancer: a scoping review.BJC reports · 2026Review
- Article
- Metformin in Colorectal Cancer: Epidemiological Evidence, Predictive Biomarkers, and Implications for Prevention and Treatment.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMillions of people die from cancer every year. Early cancer detection is crucial for ensuring higher survival rates, as it provides an opportunity for timely medical interventions. This paper proposes a multi-level cancer classification system that uses plasma cfDNA/ctDNA mutations and protein biomarkers to identify seven distinct cancer types: colorectal, breast, upper gastrointestinal, lung, pancreas, ovarian, and liver.
resultsThe proposed system employs a multi-stage binary classification framework where each stage is customized for a specific cancer type. A majority vote feature selection process is employed by combining six feature selectors: Information Value, Chi-Square, Random Forest Feature Importance, Extra Tree Feature Importance, Recursive Feature Elimination, and L1 Regularization. Following the feature selection process, classifiers-including eXtreme Gradient Boosting, Random Forest, Extra Tree, and Quadratic Discriminant Analysis-are customized for each cancer type individually or in an ensemble soft voting setup to optimize predictive accuracy. The proposed system outperformed previously published results, achieving an AUC of 98.2% and an accuracy of 96.21%. To ensure reproducibility of the results, the trained models and the dataset used in this study are made publicly available via the GitHub repository ( https://github.com/SaraEl-Metwally/Towards-Precision-Oncology ).
conclusionThe identified biomarkers enhance the interpretability of the diagnosis, facilitating more informed decision-making. The system's performance underscores its effectiveness in tissue localization, contributing to improved patient outcomes through timely medical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.